ReviewSN comprehensive clinical medicine2020
Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.
Review in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Role of nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: an updated systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Trial
- Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.Acta pharmacologica Sinica · 2022Review
- Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With Coronavirus Disease-19.Frontiers in cardiovascular medicine · 2022Article
- Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.Immunopharmacology and immunotoxicology · 2021Review
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
- Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Review
- A telehealth-based randomized controlled trial: A model for outpatient trials of off-label medications during the COVID-19 pandemic.Clinical trials (London, England) · 2021Article
- The find of COVID-19 vaccine: Challenges and opportunities.Journal of infection and public health · 2021Review
- COVID-19 cardiac injury and the use of colchicine.BMJ case reports · 2021Article
- Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.Frontiers in pharmacology · 2020Review
- Arrhythmia in COVID-19.SN comprehensive clinical medicine · 2020Review
- A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges.SN comprehensive clinical medicine · 2020Review
- Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19.Reumatologia · 2020Article
- The adjuvant therapy of edible herbal product including colchicum bulb, olive leaf, black cumin seeds, lavender flower, and ginger rhizome on the outcome of patients with severe and critical COVID-19: A double-blind randomized controlled clinical trial.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease-19 (COVID-19) may result in serious complications involving several organ systems, including myocardial tissue. An exaggerated host inflammatory response, described as a cytokine storm, has been linked to play a major role in these complications. Colchicine and other pharmaceutical agents have been proposed to counter the cytokine storm and improve outcomes. In this exploratory review, we utilized a PubMed and Cochrane Database search aiming to identify the biochemical characteristics of the cytokine storm as well as to identify the potential effect of colchicine on these inflammatory biomarkers. The research yielded 30 reports describing the characteristics of the cytokine storm and 44 reports describing the effect of colchicine on various inflammatory biomarkers. According to our research, colchicine may be an agent of interest in the treatment of COVID-19 via its anti-inflammatory properties. However, there are potential drug interactions with cytochrome P450 3A4 inhibitors resulting in acute colchicine toxicities. Additionally, there is scarce evidence regarding the efficacy of colchicine in the acute phase of disease, since most trials evaluated its effect in chronic conditions. In this direction, our team proposes three different hypotheses for evaluating the place of colchicine in the treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.